ZYBRESTAT(TM) Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer
June 06, 2011 16:45 ET
|
Mateon Therapeutics
Median Overall Survival Extended by 1.2 Months for ZYBRESTAT Patients
One-Year Survival Almost Tripled With ZYBRESTAT Plus
Chemotherapy Compared to Chemotherapy Alone (26% vs....
OXiGENE Complies With NASDAQ Listing Requirements
June 06, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Reports Encouraging Data From Phase 2 Trial of ZYBRESTAT(TM) in Non-small Cell Lung Cancer
June 04, 2011 15:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Clinical Data From FACT and FALCON Studies to be Presented at ASCO
May 18, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 18, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Reports First Quarter 2011 Financial Results
May 12, 2011 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Initiation of Phase 1 Trial of OXi4503 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
May 12, 2011 08:00 ET
|
Mateon Therapeutics
OXi4503 is a Novel, Dual-Action Vascular Disrupting Agent
The Leukemia & Lymphoma Society to Provide Study Support
SOUTH SAN FRANCISCO, Calif., May 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE,...
OXiGENE Announces First Quarter 2011 Earnings Conference Call and Webcast
May 06, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces First Patient Enrolled in Phase 2 Study of ZYBRESTAT in Patients With Ovarian Cancer
April 11, 2011 08:17 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 11, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE'S Novel Cathepsin L Inhibitors Demonstrate Antitumor Efficacy in Preclinical Studies
April 04, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Receives Meeting Minutes from FDA Type C Meeting on ZYBRESTAT(TM) Anaplastic Thyroid Program
March 21, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 21, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...